Lemzoparlimab

DB17572InvestigationalProtein Based Therapies

Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax...

Mechanism: Lemzoparlimab is an antagonist of the cell surface antigen CD47.
Curator reviewed · 2 references
Also known as: Immunoglobulin g4(228-proline), anti-(human cd47 antigen) (human monoclonal tj011133 .gamma.4-chain), disulfide with human monoclonal tj011133 .kappa.-chain, dimer
Code names: TJ-011133

Resolves to

Compound

UNII0H2XLR2IKWCAS2377483-71-9

Targets

Q08722CD47

What you can answer from here — as of June 16, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lemzoparlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account